7th November 2016
Innovative biotechnology company, Axim Biotechnologies Inc has appointed Grayling in the US to support its Investor Relations and Public Relations’ needs.
Axim Biotechnologies is engaged in the research and development, and production of pharmaceutical, nutriceutical and cosmetic products, as well as the procurement of genetically and nano-controlled active ingredients. The company’s particular focus is on the development of treatments for pain, spasticity, anxiety and other medical disorders using cannabinoids-based products. Pharmaceutical R&D aims to deliver systems and active pharmaceutical ingredients for treating conditions such as Parkinson's disease, Alzheimer's disease, restless leg syndrome and Crohn's disease.
Presently, the company is conducting clinical studies of MedChewRx, a pharmaceutical chewing gum containing cannabinoids. The company is in the process of getting FDA and EMA regulatory approval to launch this product in 2017, and it is in regard to this that Grayling is providing support.
Grayling’s efforts will be driven by New York based executive vice president, Lucia Domville. She says: “This is a fascinating company that is really pushing the boundaries with its research, and we are thrilled to be their partner.”
13th February 2018
Cyber security company puts trust in Grayling
Cyber security company, Anomali selected Grayling to handle its North American communications and cement its reputation as a leader in the emerging threat intelligence-sharing sector. The San...Read More
13th February 2018
Grayling helps Coinbase weather the crypto-boom
With Bitcoin and other cryptocurrencies dominating dinner-table conversation over the holidays, Coinbase, the largest and most trusted cryptoexchange in the US, witnessed an unprecedented surge in...Read More
9th January 2018
New Leadership for Grayling New York
Grayling has promoted Lucia Domville to the newly created post of Managing Director, New York. Domville, a veteran of the agency, was previously running Grayling’s successful Investor Relations...Read More